14

May2015
PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada.  The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the ... Read More

04

May2015
In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe.  The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain ... Read More

09

Feb2015
PDCI Market Access Inc. interviewed a representative from one of the pan-Canadian Pharmaceutical Alliance (pCPA) lead provinces and has produced an article providing guidance for negotiating with the pCPA. The pCPA has completed approximately 50 negotiations since it was established in 2010, but stakeholders are still looking for greater transparency ... Read More

07

Oct2014
PDCI Market Access has completed its benchmarking survey on the pan-Canadian Pharmaceutical Alliance (PCPA).  We received responses from manufacturers of 7 products that have successfully navigated this important reimbursement process.  The purpose of the survey was to gain a better understanding of the PCPA experience from the company perspective. The survey ... Read More

20

Mar2014
Order Form “Anytime you get something on the table that generates cost-savings, people perk up” Public drug plan representative “Patients want drug access—effective medicines to Canadians in a timely manner. The role of SEBs will be to provide Canadian patients a range of drugs at a range of ... Read More

20

Mar2014
Order Form This special report (25 pages) provides an overview of the Canadian pharmaceutical pricing and reimbursement environment. It includes descriptions of the health care system and pharmaceutical market, and then discusses pharmaceutical pricing including the Patented ... Read More

20

Mar2014
2002 Update Now Available   Download the full 2002 report Under a fully funded, publicly administered, national pharmacare program, government spending on prescribed drugs could increase by as much as $8.1 billion and would result in a dramatic shift in funding from the private sector to the public sector. The study, ... Read More

20

Mar2014
Abstract OBJECTIVE. This paper compares the prices of top selling generic drugs in Canada with prices for comparable generic products in the United States. METHODS. We examined the prices of 27 top selling (in 2001) generic prescription medicines in Canada that were marketed in both Canada and the United States. The sample ... Read More

20

Mar2014
Download the full report (66 Kb): Canada's Pharmaceutical Balance of Trade (PDF) The purpose of this study is to develop an economic analysis of the Canadian balance of trade in pharmaceuticals. The study presents historical trends in pharmaceutical trade, makes comparisons with other high technology sectors, and outlines opportunities and ... Read More

20

Mar2014
Download the full report (100 Kb): C-91: Background Study on Drug Costs and Benefits (PDF) This study examines the costs and benefits of pharmaceuticals in relation to the C-91 amendments to the Patent Act. The report is divided into two volumes. Volume 1 presents an analysis of the costs and ... Read More